2022
Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis
Doria D, Santin A, Tuszynski J, Scheim D, Aminpour M. Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. BioMedInformatics 2022, 2: 553-564. DOI: 10.3390/biomedinformatics2040035.Peer-Reviewed Original ResearchSpike 1 proteinCholinergic anti-inflammatory pathwayAnti-inflammatory pathwayGenetic alterationsParasympathetic nervous systemOmicron infectionCOVID-19 variantsAutonomic dysregulationClinical dataPreclinical resultsNatural immunitySevere formAnimal modelsNervous systemΑ7nAChRTherapeutic antibodiesAttenuation of virulenceCOVID-19InfectionPrevious variantsAttenuated natureOmicronDominant strainAlterationsHumans
2021
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Santin A, Scheim D, McCullough P, Yagisawa M, Borody T. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes And New Infections 2021, 43: 100924. PMID: 34466270, PMCID: PMC8383101, DOI: 10.1016/j.nmni.2021.100924.Peer-Reviewed Original ResearchMultifaceted drugSARS-CoV-2 spike proteinCOVID-19SARS-CoV-2Such inpatientsOutpatient treatmentClinical trialsDevastating tropical diseasesGlobal scourgeRelative riskCOVID-19 fatalitiesIVM treatmentTreatment RCTsAnimal modelsExcess deathsFull efficacyInfectious diseasesTropical diseasesSpike proteinIvermectinTreatmentDiseaseBiological mechanismsDrugsDeath
2019
Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs
Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM. Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs. Frontiers In Oncology 2019, 9: 9. PMID: 30723704, PMCID: PMC6349777, DOI: 10.3389/fonc.2019.00009.Peer-Reviewed Original ResearchPreclinical animal modelsSCID pigsOvarian carcinomaAnimal modelsEar tissueLate-stage diseaseLethal gynecologic malignancyOvarian cancer researchImmunodeficient pigsGynecologic malignanciesCarcinoma cell linesImmunohistochemical phenotypeCytokeratin 7Ovarian cancerXenotransplantation modelNeck musclesOrthotopic modelTumor massOvCa cellsPapillary carcinoma cell lineCarcinomaControl pigsClaudin-4Claudin-3Tumors
1996
Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat
Government. T, Rose, Tocco, Granger, DiSaia, Hamilton, Santin, Hiserodt. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. American Journal Of Obstetrics And Gynecology 1996, 175: 593-599. PMID: 8828419, DOI: 10.1053/ob.1996.v175.a73595.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsDisease Models, AnimalEpitheliumFemaleFlow CytometryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInjections, IntraperitonealIntercellular Adhesion Molecule-1MiceMice, NudeNeoplasm TransplantationOvarian NeoplasmsRatsRats, Inbred F344Tumor Cells, CulturedConceptsNuTu-19 cellsMajor histocompatibility complex class IEpithelial ovarian cancerHistocompatibility complex class IFischer 344 ratsComplex class IOvarian cancerCell surface antigensAnimal modelsAnimal survivalSurface antigenMajor histocompatibility complex class II antigensOvarian cancer animal modelKaplan-Meier survival analysisHuman ovarian epithelial carcinomaTumor cellsCell linesClass IClass II antigensExperimental animal modelsViable tumor cellsFemale athymic miceOvarian epithelial carcinomaParental tumor cellsUseful animal model